

News Release

Lonza Pharma&Biotech Launches Ibex™ Solutions – An Innovative New Concept in Biological Manufacturing and Development

Visp, Switzerland, 26 July 2017 – Lonza's commitment to constant innovation and adding value to its customers and partners is today demonstrated by the launch of Ibex™ Solutions – a unique addition to its current offering.

Ibex™ Solutions is an innovative new biological development and manufacturing concept, coupling flexibility in facility-build-out with fully tailored business models and leveraging Lonza's expertise and service network in Visp (CH). Construction began in June with a formal groundbreaking ceremony expected in the second half of 2017. Several hundred new positions are expected to be created.

Ibex™ biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies – mammalian, microbial, cellular or bio-conjugate – and from late discovery to manufacture. This flexibility gives customers complete freedom in facility design and implementation, and the ability to respond rapidly as their needs evolve.

Responsiveness is further enhanced by the integration of the Ibex™ biomanufacturing complex into the Visp site with its experienced workforce and established service networks.

Ibex™ Solutions include highly flexible models to match and adapt to each customer's expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by 12 months or more. These advantages contribute to a significant de-risking of major strategic investment decisions.

Lonza's Pharma&Biotech COO, Marc Funk, commented: "Lonza has been creating innovative manufacturing and production solutions for 120 years, and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world. We have been working with our partners to understand what we can offer that will really change the game for them, and that's why we have created Ibex™."

Ibex™ Solutions – Features

- Modular biomanufacturing complex
- A partner with expertise in multiple technologies and proven track record
- Technology-independent construction
- Flexible engagement options
- Existing infrastructure and support networks
- Facilities embedded in the ecosystem of Visp (CH)

Ibex™ Solutions – Benefits

- Faster time-to-market
- Full build-out flexibility
- Significant reduction in investment risk
- Tailored business and ownership models, providing higher transparency and flexibility
- Cost-effective build-out and fast ramp-up
- Assured delivery, simplified with supply chain
- Stable workforce, IP protection and favorable taxation environment

Background to Ibex™ Solutions

The path to market of a modern medicine is complex and uncertain. Under the growing pressure of regulation and competition, biopharma companies must be able to solve critical development steps under tight time and budget constraints.

This process not only entails significant capex investment in technically challenging processes during both the drug substance and drug product phases of the value chain, but also management of multiple partners, which ensures quality and regulatory compliance across that continuum.

Ibex™ Solutions from Lonza provide customers with agile capability at every stage of development and manufacture.

Further information is available on www.lonza.com.

About Lonza

Following the closing of the Capsugel acquisition, Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Ibex-The Agile Advantage™ and Ibex™ are Lonza trademarks.